Guangchun Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guangchun Wang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Bo Peng
Department of Urology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publication - Haimin Zhang
Department of Urology, Chongming Branch, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China; Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200000, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai 200000, China
1 shared publication Ji Liu
Department of Urology, Chongming Branch, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China; Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200000, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai 200000, China
1 shared publicationJinliang Ni
Department of Urology, Shanghai Putuo District People’s Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publicationKeqiang Li
Department of Urology, Chongming Branch, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China; Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200000, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai 200000, China
1 shared publication- Keqiang Li
Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1850083
Case report: A case series report: recurrent urolithiasis as a risk factor for upper tract urothelial carcinoma
Introduction: Urothelial carcinoma of the bladder (UBC) and upper tract urothelial carcinoma (UTUC) are distinct malignancies with differing prognoses and molecular characteristics despite their shared histological origin. Emerging evidence suggests that chronic inflammation, often driven by specific carcinogenic exposures, plays a critical role in tumour development. While the oncogenic role of various chemical agents in UTUC is well established, the potential contribution of recurrent urolithiasis remains underappreciated and insufficiently studied. Given the frequent observation of inflammatory polyps surrounding upper tract calculi, further investigation into this association is warranted. Case presentation: This case series reports on three patients with UTUC in the context of recurrent urolithiasis. Case 1 involves a 53-year-old male patient with a history of repeated ureteric stones and inflammatory polyps who was later diagnosed with low-grade invasive urothelial carcinoma. Case 2 describes a 46-year-old female patient with bilateral renal calculi who developed high-grade invasive UTUC following long-standing calculus disease. Case 3 is a 57-year-old male patient who had recently ingested herbal medicine containing aristolochic acid and was found to have high-grade UTUC, with concurrent urolithiasis potentially contributing to carcinogenesis. In each instance, urothelial carcinoma was initially concealed by polypoid lesions surrounding impacted stones, highlighting the associated diagnostic challenges. Conclusion: This case series underscores the potential oncogenic role of chronic inflammation induced by recurrent upper urinary tract calculi. Persistent stone-related mucosal injury may contribute to UTUC pathogenesis. Clinicians should maintain a high index of suspicion and perform targeted biopsies of polypoid lesions encountered during the endoscopic management of urolithiasis. Enhanced awareness may facilitate earlier detection and intervention, particularly in patients with recurrent calculus disease.
- 1 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1850083
Open AccessCase report: A case series report: recurrent urolithiasis as a risk factor for upper tract urothelial carcinoma
Introduction: Urothelial carcinoma of the bladder (UBC) and upper tract urothelial carcinoma (UTUC) are distinct malignancies with differing prognoses and molecular characteristics despite their shared histological origin. Emerging evidence suggests that chronic inflammation, often driven by specific carcinogenic exposures, plays a critical role in tumour development. While the oncogenic role of various chemical agents in UTUC is well established, the potential contribution of recurrent urolithiasis remains underappreciated and insufficiently studied. Given the frequent observation of inflammatory polyps surrounding upper tract calculi, further investigation into this association is warranted. Case presentation: This case series reports on three patients with UTUC in the context of recurrent urolithiasis. Case 1 involves a 53-year-old male patient with a history of repeated ureteric stones and inflammatory polyps who was later diagnosed with low-grade invasive urothelial carcinoma. Case 2 describes a 46-year-old female patient with bilateral renal calculi who developed high-grade invasive UTUC following long-standing calculus disease. Case 3 is a 57-year-old male patient who had recently ingested herbal medicine containing aristolochic acid and was found to have high-grade UTUC, with concurrent urolithiasis potentially contributing to carcinogenesis. In each instance, urothelial carcinoma was initially concealed by polypoid lesions surrounding impacted stones, highlighting the associated diagnostic challenges. Conclusion: This case series underscores the potential oncogenic role of chronic inflammation induced by recurrent upper urinary tract calculi. Persistent stone-related mucosal injury may contribute to UTUC pathogenesis. Clinicians should maintain a high index of suspicion and perform targeted biopsies of polypoid lesions encountered during the endoscopic management of urolithiasis. Enhanced awareness may facilitate earlier detection and intervention, particularly in patients with recurrent calculus disease.
- 20 June 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 185, 117038
LGALS1 promotes the malignant progression and sunitinib resistance of clear cell renal cell carcinoma by reprogramming fatty acid metabolism
- 20 June 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 185, 117038
LGALS1 promotes the malignant progression and sunitinib resistance of clear cell renal cell carcinoma by reprogramming fatty acid metabolism
- Open Access
- 8 October 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-13
Identifying effects of volatile organic compounds exposure on kidney stone prevalence in U.S. adults: a cross-sectional analysis of NHANES 2007–2020
Our aim was to comprehensively investigate the relationship between blood volatile organic compounds (VOCs) and kidney stone prevalence for U.S. adults. In this cross-sectional study, 10,052 participants from the 2007–2020 National Health and Nutrition Examination Survey (NHANES) were included. Multivariate logistic regression model was employed to investigate the association between 9 blood VOCs and kidney stones. We explored the dose–response relationship between blood VOCs and kidney stones using restricted cubic spline (RCS) analysis. Additionally, weighted quantile sum (WQS) regression model was performed to assess the overall association of 9 blood VOCs with kidney stones. Finally, subgroup analyses were conducted to identify the findings in different populations at high prevalence. Logistic regression analysis and dose–response risk curves revealed that blood benzene (aOR = 1.308, 95% CI: 1.118–1.530, P = 0.001), blood ethylbenzene (aOR = 1.280, 95% CI: 1.054–1.554, P = 0.013), blood m-/p-xylene (aOR = 1.187, 95% CI: 1.008–1.398, P = 0.040), blood 2,5-dimethylfuran (aOR = 1.319, 95% CI: 1.135–1.533, P < 0.001) and blood furan (aOR = 1.698, 95% CI: 1.305–2.209, P < 0.001) were positively associated with the prevalence of kidney stones. WQS regression analysis revealed that exposure to mixed blood VOCs was positively correlated with kidney stone prevalence (OR = 1.34, 95% CI: 1.14–1.57), with furans carrying the greatest weight. Subgroup analyses suggested that kidney stones were more susceptible to the effects of blood VOCs in young and middle-aged, female, overweight and obese, non-hypertensive, and non-diabetic populations. In this study, the results indicated that high VOC exposure was positively and independently associated with kidney stones in U.S. adults. This finding highlighted the need for public health strategies to reduce VOC exposure and its role in kidney stone prevention and treatment.
- 8 October 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-13
Open AccessIdentifying effects of volatile organic compounds exposure on kidney stone prevalence in U.S. adults: a cross-sectional analysis of NHANES 2007–2020
Our aim was to comprehensively investigate the relationship between blood volatile organic compounds (VOCs) and kidney stone prevalence for U.S. adults. In this cross-sectional study, 10,052 participants from the 2007–2020 National Health and Nutrition Examination Survey (NHANES) were included. Multivariate logistic regression model was employed to investigate the association between 9 blood VOCs and kidney stones. We explored the dose–response relationship between blood VOCs and kidney stones using restricted cubic spline (RCS) analysis. Additionally, weighted quantile sum (WQS) regression model was performed to assess the overall association of 9 blood VOCs with kidney stones. Finally, subgroup analyses were conducted to identify the findings in different populations at high prevalence. Logistic regression analysis and dose–response risk curves revealed that blood benzene (aOR = 1.308, 95% CI: 1.118–1.530, P = 0.001), blood ethylbenzene (aOR = 1.280, 95% CI: 1.054–1.554, P = 0.013), blood m-/p-xylene (aOR = 1.187, 95% CI: 1.008–1.398, P = 0.040), blood 2,5-dimethylfuran (aOR = 1.319, 95% CI: 1.135–1.533, P < 0.001) and blood furan (aOR = 1.698, 95% CI: 1.305–2.209, P < 0.001) were positively associated with the prevalence of kidney stones. WQS regression analysis revealed that exposure to mixed blood VOCs was positively correlated with kidney stone prevalence (OR = 1.34, 95% CI: 1.14–1.57), with furans carrying the greatest weight. Subgroup analyses suggested that kidney stones were more susceptible to the effects of blood VOCs in young and middle-aged, female, overweight and obese, non-hypertensive, and non-diabetic populations. In this study, the results indicated that high VOC exposure was positively and independently associated with kidney stones in U.S. adults. This finding highlighted the need for public health strategies to reduce VOC exposure and its role in kidney stone prevention and treatment.